Honeywell, Recipharm to speed development of inhalers

Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

Surging demand for Korean pharma in 2023 ahead of CPHI Korea

Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings

Akums gets approval for triple combination diabetes treatment

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.

Evonik and Heraeus cooperate to expand the range of services for highly potent API

Evonik specializes in mid- to large-scale, later clinical phase HPAPIs

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models

Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x